Enanta Pharmaceuticals, Inc(ENTA)
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
- 52-Week Range
- $7.05 – $17.15
- YTD
- -17.61%
- IV Rank (30D)
- 40.2
- Straddle Price
- $2.48
- P/C Vol Ratio
- 29.29
- Market Cap
- $0.3B
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.96% |
| Beta vs SPY | 1.12 |
| Cost of Equity (CAPM) | 11.13% (VRP-adj) |
| WACC | 11.06% |
| Volatility Risk Premium | +99.3pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | -5.1% |
| DCF Horizon | 10 years explicit + fade |
| Free Cash Flow (TTM) | $-0.0B |
| Return on Equity (TTM) | -62.6% |
| Book / Price | 31.1% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 100.0% |
| FCF Margin (TTM) | -56.6% |
| Debt / Equity | 0.00 |
| Quality Score | 2/6 — normal (10y DCF) |
| SMA 50 | $13.17 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $13.01 |
| Bollinger Width / SMA20 | 166.1% (drives anchor stability) |
| Net Debt | $-0.0B |
| Market Cap | $0B |
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | |
| Peer EV/EBITDA | n/a | 0% | |
| Peer P/B | $23.42 | 19% | median 6.3× · 7 peers |
| Peer P/S | $23.57 | 19% | median 9.8× · 6 peers |
| Market Anchor (SMA50) | $13.17 | 62% | stability 63% (BB-width) |
| Options Expected (B-L 30d) | $10.85 | 0% | 5 strikes · skew -0.51 |
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834)
- Exchange
- XNAS
- Market Cap
- $0.3B
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inh…
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | -2.02% | 6 |
| Feb | +16.45% | 6 |
| Mar | -6.70% | 6 |
| Apr | -1.80% | 6 |
| May | -15.14% | 6 |
| Jun | +1.35% | 6 |
| Jul | +1.15% | 6 |
| Aug | +1.18% | 6 |
| Sep | -4.69% | 6 |
| Oct | +4.26% | 5 |
| Nov | +2.38% | 5 |
| Dec | -2.66% | 5 |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
LLM Stock Analysis Report - ENTA
Executive Summary
Overall Assessment: NEUTRAL (Confidence Level: 7/10)
Key Drivers:
- Technical indicators suggest a potentially overbought condition, with RSI nearing 70.
- MACD is bullish, indicating momentum on the upside.
- Bollinger Bands indicate an overbought state.
Primary Risks:
- Potential for a pullback or consolidation due to overbought conditions.
- Volatility could increase if market sentiment shifts.
Recent News Sentiment Impact: No recent news available; analysis focused on technical indicators.
Technical Analysis
Trend Direction: Medium-term (1-3 months) uptrend
Support/Resistance Levels: Key price levels from moving averages and technical patterns: + Upper Bollinger Band ($16.52) + EMA 12 ($15.43)
Momentum Signals: * RSI interpretation: Overbought (>70), indicating potential sell signal. * MACD signal: Bullish, indicating momentum on the upside. * Bollinger Bands position: Overbought.
Volume Analysis: Volume trends and institutional interest signals: + On-Balance Volume (OBV) trending upwards, indicating increasing buying pressure. + Volume Rate of Change (ROC) at 64.43%, indicating moderate volume activity.
News & Sentiment Analysis
Recent Headlines Summary: No recent news available
Sentiment Assessment: NEUTRAL (no significant news sentiment)
Catalyst Identification: None identified; focus on technical signals and market context.
Market Narrative: Technical signals suggest potential overbought conditions, while institutional interest remains moderate.
Risk & Volatility Assessment
Beta Interpretation: Beta 0.96 (relatively low-risk stock)
Volatility Regime: Moderate volatility - stock generally follows market
Options Market Signals: IV rank 36.8% (Medium), put/call ratios indicating bullish sentiment, and open interest suggesting moderate activity.
Downside Protection: Support levels ($14.83, $12.86) and risk management considerations: stop-loss at $15.43.
Market Context & Positioning
Sector Performance: ENTA outperforming the sector/market
Institutional Activity: Moderate volume and interest signals.
Correlation Analysis: Correlation with market (R-squared interpretation): 0.16, indicating moderate correlation.
Relative Valuation: ENTA positioned within a trading range.
Key Levels & Action Items
Critical Price Levels: Upper Bollinger Band ($16.52), EMA 12 ($15.43)
Breakout/Breakdown Levels: None identified; focus on technical signals and market context.
Time-Sensitive Catalysts: None identified; focus on technical signals and market context.
Risk Management: Stop-loss at $15.43, considering a potential pullback or consolidation due to overbought conditions.
This analysis provides an objective view of ENTA's stock performance, highlighting both bullish and bearish cases. Technical indicators suggest a potentially overbought condition, while institutional interest remains moderate. Risk management considerations focus on potential support levels and stop-loss strategies.
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2024-11-25 | Pre-Market | 22.48% | 5.57% | 0.25x | Within |
| 2025-02-10 | After-Close | 36.73% | 14.08% | 0.38x | Within |
| 2025-05-12 | After-Close | 101.80% | 4.95% | 0.05x | Within |
| 2025-08-11 | After-Close | 30.45% | 4.67% | 0.15x | Within |
| 2025-11-17 | After-Close | 17.75% | 3.59% | 0.20x | Within |
| 2026-02-09 | Pre-Market | 15.57% | 1.93% | 0.12x | Within |
| 2026-05-11 | Pre-Market | 19.56% | 0.78% | 0.04x | Within |
| 2026-08-10 | After-Close | 10.50% | 2.10% | 0.20x | Within |
- IV Rank (30D)
- 40.2
- IV Rank (7D)
- 40.2
- Avg IV
- 140.2%
- Straddle (30D)
- $2.48
- Straddle (7D)
- $2.48
- P/C Volume
- 29.29
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Enter a ticker to render the implied volatility surface.
Enter a ticker to render the implied volatility smile.
- Beta (1Y vs SPY)
- 1.00
- Correlation (SPY)
- 12.2%
- R²
- 0.01
- Ann. Volatility
- 106.7%
- SPY Volatility
- 13.0%
Above average volatility - stock moves with market amplification
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | CITADEL ADVISORS LLC Custodian | $382.00K | 58.35% | 2026-06-30 |
| 2 | SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian | $185.17K | 28.29% | 2026-06-30 |
| 3 | SIMPLEX TRADING, LLC Custodian | $84.56K | 12.92% | 2026-06-30 |
| 4 | GROUP ONE TRADING LLC Custodian | $2.92K | 0.45% | 2026-06-30 |
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian | $295.97K | 86.75% | 2026-06-30 |
| 2 | SIMPLEX TRADING, LLC Custodian | $42.28K | 12.39% | 2026-06-30 |
| 3 | GROUP ONE TRADING LLC Custodian | $2.92K | 0.85% | 2026-06-30 |
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-08-10 | Scott T. Rottinghaus | Chief Medical Officer | Tax (F) | −1,467 | $13.34 | -$19.6K | EDGAR |
| 2026-03-13 | Lesley Russell | Director | Grant (A) | +20,000 opt | — | EDGAR | |
| 2026-03-13 | BRUCE L A CARTER | Director | Grant (A) | +20,000 opt | — | EDGAR | |
| 2026-03-13 | Kristine Peterson | Director | Grant (A) | +20,000 opt | — | EDGAR | |
| 2026-03-13 | Terry Vance | Director | Grant (A) | +20,000 opt | — | EDGAR | |
| 2026-03-13 | MARK G FOLETTA | Director | Grant (A) | +20,000 opt | — | EDGAR | |
| 2026-03-13 | Yujiro S Hata | Director | Grant (A) | +20,000 opt | — | EDGAR | |
| 2026-02-13 | Scott T. Rottinghaus | Chief Medical Officer | Mixed | +3,462 | $14.25 | -$48.6K | EDGAR |
| 2026-02-13 | Matthew Paul Kowalsky | Chief Legal Officer | Mixed | +3,591 | $14.25 | -$27.1K | EDGAR |
| 2026-02-13 | Tara Lynn Kieffer | Chief Product Strategy Officer | Mixed | +3,305 | $14.25 | -$46.4K | EDGAR |
| 2026-02-13 | Brendan Luu | Chief Business Officer | Mixed | +3,305 | $14.25 | -$46.4K | EDGAR |
| 2026-02-13 | Jay R. Luly | President and CEO | Mixed | +13,845 | $14.25 | -$87.7K | EDGAR |
| 2026-02-13 | Yat Sun Or | Chief Scientific Officer | Mixed | +3,462 | $14.25 | -$48.6K | EDGAR |
| 2025-12-05 | Harry R. Trout III | See Remarks | Sell (S) | −542 | $14.23 | -$7.7K | EDGAR |
| 2025-12-05 | Yat Sun Or | Chief Scientific Officer | Sell (S) | −2,390 | $14.23 | -$34.0K | EDGAR |
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | SHIONOGI & CO LTD | 10%+ Owner | 1,599,760 | $19.01M | $0 | 1 | 2013-03-28 |
| 2 | OBP III - Holdings LLC | 10%+ Owner | 1,490,028 | $17.70M | -$28.21M | 1 | 2013-10-02 |
| 3 | OBP (Bermuda) III - Holdings LLC | 10%+ Owner | 1,480,238 | $17.59M | -$1.73M | 1 | 2013-10-04 |
| 4 | Jay R. Luly | President and CEO | 862,826 | $10.25M | -$13.70M | 62 | 2026-02-13 |
| 5 | Marc E. Goldberg | Director | 547,606 | $6.51M | -$1.48M | 3 | 2013-12-06 |
| 6 | Hubert Birner | 10%+ Owner | 459,064 | $5.45M | -$170.53M | 1 | 2014-03-07 |
| 7 | TVM V Life Science Ventures Management GmbH & Co. KG | 10%+ Owner | 389,835 | $4.63M | -$3.62M | 1 | 2014-02-20 |
| 8 | HELMUT SCHUHSLER | Director | 388,617 | $4.62M | -$1.06M | 4 | 2014-02-25 |
| 9 | Yat Sun Or | Chief Scientific Officer | 378,267 | $4.49M | -$7.74M | 55 | 2026-02-13 |
| 10 | TVM IV Management GmbH & Co. KG | 10%+ Owner | 361,320 | $4.29M | -$90.13M | 1 | 2014-02-27 |
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. Amendments (Form 144/A) and post-cancellation refilings can inflate this if you sum naively; the rollup above excludes filings with zero stated value.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2025-12-05 | Luly Jay R. | Officer, Director | 4,743 | $67.5K | 2025-12-05 | Morgan Stanley Smith Barney | — | EDGAR |
| 2024-07-11 | Scott T. Rottinghaus | Officer | 11,945 | $178.7K | 2024-07-11 | J.P. Morgan Securities LLC | 10b5-1 | EDGAR |
| 2024-06-17 | Tara Lynn Kieffer | Officer | 7,266 | $92.4K | 2024-06-17 | J.P. Morgan Securities LLC | 10b5-1 | EDGAR |
| 2023-12-12 | Vance Terry | Director | 15,295 | $138.6K | 2023-12-13 | Pershing LLC | — | EDGAR |
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
| P/B Ratio | 3.5 |
| P/S Ratio | 5.4 |
| EV/EBITDA | -5.9 |
| TTM Revenue | $0.1B |
| TTM Net Income | $-0.1B |
| TTM EPS | $-2.42 |
| ROE | -62.6% |